{"entity":{"id":"response-2","kind":"trial","name":"RESPONSE-2","aka":[],"tldr":"RESPONSE-2 extended ruxolitinib's benefit to PV patients without an enlarged spleen: three times as many reached haematocrit control.","summary":"RESPONSE-2 randomised 149 patients with hydroxyurea-resistant or intolerant PV and no palpable spleen to ruxolitinib or best available therapy. Haematocrit control at week 28, the primary endpoint, was achieved by 62 percent on ruxolitinib versus 19 percent on best available therapy (Passamonti and colleagues, Lancet Oncology 2017), with better symptom scores.","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02038036","url":"https://clinicaltrials.gov/study/NCT02038036"}],"tags":["polycythaemia-vera","mpn"],"related":[],"cancers":["polycythaemia-vera"],"sections":[],"technologies":[],"targets":[],"drugs":["ruxolitinib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02038036","phase":"3","setting":"Hydroxyurea-resistant or intolerant polycythaemia vera without splenomegaly: ruxolitinib versus best available therapy","sponsor":"Novartis","result":"Haematocrit control at week 28: 62% vs 19%.","yearReported":2017,"enrolled":149,"outcomes":[{"endpoint":"Haematocrit control at week 28","primary":true,"unit":"%","arms":[{"name":"Ruxolitinib","n":74,"value":62},{"name":"Best available therapy","n":75,"value":19}]}]},"route":"/trials/response-2/","neighbours":{"cancer":[{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"drug":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}